Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is a promising late-stage biopharmaceutical company with a strong focus on developing oral, small-molecule drug candidates for the treatment of chronic diseases, such as type 1 diabetes. Their lead candidate, cadisegliatin, has demonstrated positive clinical data and has received Breakthrough Therapy Designation, positioning it well for success in the Phase 3 CATT1 trial. Additionally, the company's plans to expand the use of cadisegliatin through the Hybrid CATT1 trial and its potential as a complement to emerging curative therapies, including cell therapy and gene therapy, further support a positive outlook for this stock.

Bears say

vTv Therapeutics is facing several challenges that may hinder its success in the coming years. Its current pipeline, led by cadisegliatin, is the company's main hope for commercial success, with a forecasted peak revenue of $1.6 billion. However, the company faces significant risks, including potential safety concerns, lower than expected efficacy, and intense competition in the market, which could all significantly impact its bottom line and delay its path to profitability and success. Furthermore, the company is heavily dependent on third-party suppliers for its product candidates, which could lead to delays in clinical trials and ultimately affect its ability to bring a successful product to market.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.